Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-089670
Filing Date
2025-06-24
Accepted
2025-06-24 19:10:56
Documents
1
Period of Report
2025-06-20

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5853
  Complete submission text file 0000950170-25-089670.txt   7424
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Issuer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BLVD., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Cook Jennifer E. (Reporting) CIK: 0001754371 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38959 | Film No.: 251070510